Eprosartan Mesylate 600mg (NDC: 0378-6629)

Name:

Eprosartan Mesylate 600mg

NDC:

0378-6629

Generic Name:

Eprosartan Mesylate

Strength:

600mg

Form:

Tablet

Labeler:

Mylan Pharmaceuticals, Inc.

Shape:

Oval

Color:

White

Imprint:

M;EN3

Medication Class:

ARBs

Active Ingredient:

Eprosartan Mesylate

Pregnancy Category:

Usually not recommended (Category D)

Illustration:

Pill Illustration: Eprosartan Mesylate 600mg (0378-6629)

About this medication

Eprosartan Mesylate is the name of the medication. It comes in the form of a tablet, and should be taken by mouth. It belongs to a class of medications called ARBs.

Why is this medication prescribed

This medication is used for lowering high blood pressure (also called hypertension). It is also used to treat heart failure and can help to prevent kidney failure in people with diabetes. Ask your physician why he or she gave you this medication.

How does it work

Eprosartan Mesylate belongs to a group of medications called Angiotensin II Receptor Blockers. It works by blocking a hormone in your body that normally causes blood vessels to narrow. It relaxes the blood vessels and makes them wider. As a result, your blood pressure goes down and it helps your heart.

How to use it

This medication comes as a tablet. You should put it in your mouth and swallow it with a glass of water. Do not chew, break or crush it. Swallow it whole.

What to do if you are pregnant

Tell your physician if you are pregnant or planning to become pregnant. Studies show that when pregnant women use the medication, some babies are born with problems related to the medication. However, in some serious situations, the medication may still help the mother and the baby more than it might harm. Talk with your physician about it.

More Information

Read more about Eprosartan Mesylate 600mg on the FDA website.

Last Update: May 13th 2017
Data sources: Label (May 13th 2017), FDA (May 31st 2015)

MyRx.tv and Telesofia Medical Ltd. are not affiliated with the FDA or with Mylan Pharmaceuticals, Inc..